Patent application number | Description | Published |
20090148437 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS - The present invention relates to polypeptides e.g. protease resistant polypeptides, immunoglobulin (antibody) single variable domains e.g. which are protease resistant and also to vascular endothelial growth factor (VEGF) antagonists comprising these. The invention further relates to uses, formulations, and compositions comprising such polypeptides e.g. for delivery to the eye. | 06-11-2009 |
20110008345 | ANTIGEN-BINDING CONSTRUCTS - The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 01-13-2011 |
20120134982 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS - The present invention relates to polypeptides e.g. protease resistant polypeptides, immunoglobulin (antibody) single variable domains e.g. which are protease resistant and also to vascular endothelial growth factor (VEGF) antagonists comprising these. The invention further relates to uses, formulations, and compositions comprising such polypeptides e.g. for delivery to the eye. | 05-31-2012 |
20130236467 | MULTISPECIFIC ANTIGEN BINDING PROTEINS TARGETING HGF - The invention relates to combinations of HGF-antagonists with VEGF antagonists, and provides antigen-binding proteins which bind to HGF comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding protein has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 09-12-2013 |
Patent application number | Description | Published |
20100247515 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS - The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis. | 09-30-2010 |
20100254995 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS - The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis. | 10-07-2010 |
20120064064 | ANTIGEN-BINDING PROTEINS - The present invention relates to antigen binding proteins comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises an epitope binding domain linked to the n-terminus of CH1-CH2-CH3, and the light chain comprises an epitope binding domain linked to the n-terminus of CL, wherein one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin heavy chain, and/or one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin light chain, methods for making such proteins, and uses thereof. | 03-15-2012 |
20120076787 | COMBINATION OF A TNF-ALPHA ANTAGONIST AND A VEGF ANTAGONIST FOR USE IN THE TREATMENT OR PREVENTION OF DISEASES OF THE EYE - The invention relates to combinations of TNFα antagonists with VEGF antagonists for use in treating diseases of the eye, and provides antigen-binding proteins which bind to TNFα or a TNFα receptor and/or VEGF or a VEGF receptor. | 03-29-2012 |
Patent application number | Description | Published |
20090148905 | ANTIGEN-BINDING CONSTRUCTS - The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 06-11-2009 |
20110256122 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS - The present disclosure relates to immunoglobulin single variable domains (dAbs) e.g., dAbs which are protease resistant, and also to formulations, and compositions comprising such dAbs for ocular delivery and to their uses to treat ocular diseases and conditions. | 10-20-2011 |
20130041136 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 02-14-2013 |
20140205604 | ANTIGEN BINDING CONSTRUCTS - The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD). diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularisation, and polynucleotide sequences encoding said antigen binding constructs. | 07-24-2014 |
Patent application number | Description | Published |
20140270203 | Method and apparatus for determining digital media audibility - A method of determining the audio level of a network partner media player, wherein, when media playing on a terminal media player running on a terminal originates from an external media source, the method comprises obtaining activity information from the terminal, obtaining activity information from the terminal media player, obtaining activity information from an external source media player associated with the external media source, and analysing the activity information from the terminal, the activity information from the terminal media player, the activity information from the external media source media player, whereby the audio level of the network partner media player is determined. | 09-18-2014 |
20140278911 | METHOD AND APPARATUS FOR DETERMINING DIGITAL MEDIA AUDIBILITY - A method of determining the audio level of a network partner media player, wherein, when media playing on a terminal media player running on a terminal originates from an external media source, the method comprises obtaining activity information from the terminal, obtaining activity information from the terminal media player, obtaining activity information from an external source media player associated with the external media source, and analysing the activity information from the terminal, the activity information from the terminal media player, the activity information from the external media source media player, whereby the audio level of the network partner media player is determined. | 09-18-2014 |